Cover of Accelerating the Development of New Drugs and Diagnostics

Accelerating the Development of New Drugs and Diagnostics

Maximizing the Impact of the Cures Acceleration Network

Workshop Summary

.

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-26116-6ISBN-10: 0-309-26116-3
Copyright © 2012, National Academy of Sciences.
Read

Excerpt

This public workshop considered options and opportunities to maximize the usefulness and impact of the Cures Acceleration Network (CAN) program in order to advance translational sciences. The workshop objectives were to:

  • Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science.

    Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN—for example, FDA, the U.S. Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ).

  • Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities.

    Consideration of the CAN authorities will specifically explore the flexible research, or “other transaction,” authority and will reference existing efforts in which such authority is currently applied across other federal agencies—for example, DARPA, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

  • Explore promising models for public–private collaborations that could be strengthened or facilitated by activities under CAN.

    Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers.

    Discuss the respective roles of multiple sectors, including, for example, the pharmaceutical and biotechnology industries, venture capital and private equity, and patient advocacy groups.

  • Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.